Studying why some endometrial cancers respond to immunotherapy
Studies biological markers that may predict response to immunotherapy in endometrial cancer patients.
Plain-language title generated from the registry record
Registry title: DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- European Institute of OncologyMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- European Institute of Oncology
- Trial code
- NCT07690540
- Record updated
- 8 July 2026
- Original description
In recent years, the introduction of immune checkpoint inhibitors (ICI) in combination with chemotherapy has significantly changed the management of advanced and recurrent Endometrial Cancer (EC).Read full original descriptionShow less
INVESTIGATING DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER: A MULTIDIMENSIONAL APPROACH IN A UNIQUE POPULATION (iDEA PROJECT)
In recent years, the introduction of immune checkpoint inhibitors (ICI) in combination with chemotherapy has significantly changed the management of advanced and recurrent Endometrial Cancer (EC).
Despite these advances, responses to immunotherapy remain heterogeneous. Not all patients with mismatch repair-deficient (dMMR) tumors derive durable benefit, while a subset of mismatch repair-proficient (pMMR) tumors may respond. In addition, ICI treatment is associated with relevant costs and immune-related toxicities, highlighting the need for improved patient selection. To date, no validated predictive biomarkers beyond mismatch repair (MMR) status are available, reflecting limited understanding of the biological mechanisms underlying sensitivity and resistance to immunotherapy in EC.
This study aims to assess and integrate molecular and epigenetic features to identify prognostic and predictive biomarkers of immunotherapy response in endometrial cancer, and to explore their functional relevance using patient-derived experimental models.
Inclusion: Age ≥ 18 years; Histologically confirmed advanced or recurrent endometrial carcinoma or carcinosarcoma; No prior treatment with immune checkpoint inhibitors; Availability of paired fresh-frozen and FFPE tumor samples; Provision of written informed consent for participation in translational research.
Exclusion: Active treatment with immunomodulatory agents at the time of sample collection (e.g., immunotherapy for autoimmune disease); Mesenchymal tumors or epithelial tumors of non-endometrial origin (e.g., ovarian cancer); Known positivity for HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV); Refusal or inability to provide informed consent by the patient or legal representative.